• Je něco špatně v tomto záznamu ?

Fabry disease revisited: Management and treatment recommendations for adult patients

A. Ortiz, DP. Germain, RJ. Desnick, J. Politei, M. Mauer, A. Burlina, C. Eng, RJ. Hopkin, D. Laney, A. Linhart, S. Waldek, E. Wallace, F. Weidemann, WR. Wilcox,

. 2018 ; 123 (4) : 416-427. [pub] 20180228

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035360

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Phenotypes vary from the "classic" phenotype, with pediatric onset and multi-organ involvement, to later-onset, a predominantly cardiac phenotype. Manifestations are diverse in female patients in part due to variations in residual enzyme activity and X chromosome inactivation patterns. Enzyme replacement therapy (ERT) and adjunctive treatments can provide significant clinical benefit. However, much of the current literature reports outcomes after late initiation of ERT, once substantial organ damage has already occurred. Updated monitoring and treatment guidelines for pediatric patients with Fabry disease have recently been published. Expert physician panels were convened to develop updated, specific guidelines for adult patients. Management of adult patients depends on 1) a personalized approach to care, reflecting the natural history of the specific disease phenotype; 2) comprehensive evaluation of disease involvement prior to ERT initiation; 3) early ERT initiation; 4) thorough routine monitoring for evidence of organ involvement in non-classic asymptomatic patients and response to therapy in treated patients; 5) use of adjuvant treatments for specific disease manifestations; and 6) management by an experienced multidisciplinary team.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035360
003      
CZ-PrNML
005      
20191015121152.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ymgme.2018.02.014 $2 doi
035    __
$a (PubMed)29530533
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ortiz, Alberto $u Unidad de Dialisis, IIS-Fundacion Jimenez Diaz, School of Medicine, UAM, IRSIN and REDINREN, Madrid, Spain. Electronic address: aortiz@fjd.es.
245    10
$a Fabry disease revisited: Management and treatment recommendations for adult patients / $c A. Ortiz, DP. Germain, RJ. Desnick, J. Politei, M. Mauer, A. Burlina, C. Eng, RJ. Hopkin, D. Laney, A. Linhart, S. Waldek, E. Wallace, F. Weidemann, WR. Wilcox,
520    9_
$a Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Phenotypes vary from the "classic" phenotype, with pediatric onset and multi-organ involvement, to later-onset, a predominantly cardiac phenotype. Manifestations are diverse in female patients in part due to variations in residual enzyme activity and X chromosome inactivation patterns. Enzyme replacement therapy (ERT) and adjunctive treatments can provide significant clinical benefit. However, much of the current literature reports outcomes after late initiation of ERT, once substantial organ damage has already occurred. Updated monitoring and treatment guidelines for pediatric patients with Fabry disease have recently been published. Expert physician panels were convened to develop updated, specific guidelines for adult patients. Management of adult patients depends on 1) a personalized approach to care, reflecting the natural history of the specific disease phenotype; 2) comprehensive evaluation of disease involvement prior to ERT initiation; 3) early ERT initiation; 4) thorough routine monitoring for evidence of organ involvement in non-classic asymptomatic patients and response to therapy in treated patients; 5) use of adjuvant treatments for specific disease manifestations; and 6) management by an experienced multidisciplinary team.
650    _2
$a dospělí $7 D000328
650    _2
$a management nemoci $7 D019468
650    12
$a enzymová substituční terapie $7 D056947
650    _2
$a Fabryho nemoc $x enzymologie $x terapie $7 D000795
650    _2
$a lidé $7 D006801
650    _2
$a alfa-galaktosidasa $x aplikace a dávkování $7 D000519
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Germain, Dominique P $u French Referral Center for Fabry disease, Division of Medical Genetics and INSERM U1179, University of Versailles, Paris-Saclay University, Montigny, France.
700    1_
$a Desnick, Robert J $u Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
700    1_
$a Politei, Juan $u Department of Neurology, Fundacion Para el Estudio de Enfermedades Neurometabolicas (FESEN), Buenos Aires, Argentina.
700    1_
$a Mauer, Michael $u Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, MN, USA.
700    1_
$a Burlina, Alessandro $u Neurological Unit, St Bassiano Hospital, Bassano del Grappa, Italy.
700    1_
$a Eng, Christine $u Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
700    1_
$a Hopkin, Robert J $u Division of Human Genetics, Cincinnati Children's Hospital Medical Center, and Department of Pediatrics University of Cincinnati College of Medicine, Cincinnati, OH, USA.
700    1_
$a Laney, Dawn $u Division of Medical Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
700    1_
$a Linhart, Aleš $u 2nd Department of Internal - Cardiovascular Medicine, First Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Waldek, Stephen $u School of Pharmacy, University of Sunderland, Sunderland, UK.
700    1_
$a Wallace, Eric $u Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.
700    1_
$a Weidemann, Frank $u Department of Internal Medicine, Katharinen-Hospital Unna, Unna, Germany.
700    1_
$a Wilcox, William R $u Division of Medical Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.
773    0_
$w MED00006573 $t Molecular genetics and metabolism $x 1096-7206 $g Roč. 123, č. 4 (2018), s. 416-427
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29530533 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191015121618 $b ABA008
999    __
$a ok $b bmc $g 1452020 $s 1073910
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 123 $c 4 $d 416-427 $e 20180228 $i 1096-7206 $m Molecular genetics and metabolism $n Mol Genet Metab $x MED00006573
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace